NCT00432185 - To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Superficial Basal Cell Carcinoma

Interventions

DRUG

PEP005

0.25% PEP005 Gel

Trial Locations (9)

Dermatology Associates of Rochester, Rochester

Park Avenue Dermatology, Orange Park

Advanced Dermatology and Cosmetic Surgery, Clermont

Rivergate Dermatology and Skin Care Center, Goodlettsville

Minnesota Clinical Studies Center, Fridley

Colorado Medical Research Center, Denver

Alta Dermatology, Mesa

Dermatology Specialists Inc., Oceanside

Skin Surgery Medical Group Inc., San Diego